Literature DB >> 15149428

Fractionation of electrograms and linking of activation during pharmacologic cardioversion of persistent atrial fibrillation in the goat.

Zhaoliang Shan1, Pepijn H Van Der Voort, Yuri Blaauw, Mattias Duytschaever, Maurits A Allessie.   

Abstract

INTRODUCTION: During atrial fibrillation (AF), there is fractionation of extracellular potentials due to head-to-tail interaction and slow conduction of fibrillation waves. We hypothesized that slowing of the rate of AF by infusion of a Class I drug would increase the degree of organization of AF. METHODS AND
RESULTS: Seven goats were instrumented with 83 epicardial electrodes on the left atrium, left atrial appendage, Bachmann's bundle, right atrium, and right atrial appendage. AF was induced and maintained by an automatic atrial fibrillator. After AF had persisted for 4 weeks, the Class IC drug cibenzoline was infused at a rate of 0.1 mg/kg/min. AF cycle length (AFCL), the percentage of fractionated potentials, conduction velocity (CV), and direction of propagation of the fibrillation waves were measured during baseline, after AFCL was increased by 20, 40, 60, and 80 ms, and shortly before cardioversion. Infusion of cibenzoline increased the mean of the median AFCLs from 96 +/- 6 ms to 207 +/- 43 ms (P < 0.0001). The temporal variation in AFCL in different parts of the atria was 8% to 20% during control and, with the exception of Bachmann's bundle, was not significantly reduced during cibenzoline infusion. CV decreased from 76 +/- 14 ms to 52 +/- 9 cm/s (P < 0.01). Cibenzoline increased the percentage of single potentials from 81%+/- 4% to 91%+/- 4% (P < 0.01) and decreased the incidence of double potentials from 14%+/- 4% to 7 +/- 5% (P < 0.01) and multiple potentials from 5%+/-% to 1%+/- 2% (P < 0.001). Whereas during control, linking (consecutive waves propagating in the same direction) during seven or more beats occurred in 9%+/- 15% of the cycles, after cibenzoline the degree of linking had increased to 40%+/- 33% (P < 0.05). During the last two beats before cardioversion, there was a sudden prolongation in AFCL from 209 +/- 37 ms to 284 +/- 92 ms (P < 0.01) and a strong reduction in fractionated potentials (from 22%+/- 12% to 6%+/- 5%, P < 0.05).
CONCLUSION: The Class IC drug cibenzoline causes a decrease in fractionation of fibrillation electrograms and an increase in the degree of linking during AF. This supports the observation that Class I drugs widen the excitable gap during AF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149428     DOI: 10.1046/j.1540-8167.2004.03402.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  10 in total

1.  Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling.

Authors:  Thomas H Everett; Emily E Wilson; Sander Verheule; Jose M Guerra; Scott Foreman; Jeffrey E Olgin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-07-28       Impact factor: 4.733

Review 2.  Catheter Ablation Targeting Complex Fractionated Atrial Electrogram in Atrial Fibrillation.

Authors:  Dennis H Lau; Stef Zeemering; Bart Maesen; Pawel Kuklik; Sander Verheule; Ulrich Schotten
Journal:  J Atr Fibrillation       Date:  2013-10-31

3.  The ECG in cardiovascular-relevant animal models of electrophysiology.

Authors:  Sven Kaese; Gerrit Frommeyer; Sander Verheule; Gunther van Loon; Josef Gehrmann; Günter Breithardt; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-06-06

Review 4.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

5.  Substrate and Trigger Ablation for Reduction of Atrial Fibrillation (STAR AF): a randomized, multicentre, international trial.

Authors:  Atul Verma; Roberto Mantovan; Laurent Macle; Guiseppe De Martino; Jian Chen; Carlos A Morillo; Paul Novak; Vittorio Calzolari; Peter G Guerra; Girish Nair; Esteban G Torrecilla; Yaariv Khaykin
Journal:  Eur Heart J       Date:  2010-03-09       Impact factor: 29.983

6.  High-resolution analysis of the surface P wave as a measure of atrial electrophysiological substrate.

Authors:  Damian P Redfearn; Joanne Lane; Kevin Ward; Peter J Stafford
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-01       Impact factor: 1.468

7.  Use of antiarrhythmic drugs during ablation of persistent atrial fibrillation: observations from a large single-centre cohort.

Authors:  Jakob Lüker; Arian Sultan; Susanne Sehner; Boris Hoffmann; Helge Servatius; Stephan Willems; Daniel Steven
Journal:  Heart Vessels       Date:  2015-11-06       Impact factor: 2.037

8.  Minimally invasive mapping guided surgical treatment of atrial fibrillation. Utopia or near future?

Authors:  Thomas J van Brakel; Gil Bolotin; M A Allessie; Jos G Maessen
Journal:  Indian Pacing Electrophysiol J       Date:  2006-10-01

9.  The Acetylcholine-Activated Potassium Current Inhibitor XAF-1407 Terminates Persistent Atrial Fibrillation in Goats.

Authors:  Vladimír Sobota; Giulia Gatta; Arne van Hunnik; Iris van Tuijn; Marion Kuiper; James Milnes; Thomas Jespersen; Ulrich Schotten; Sander Verheule
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

Review 10.  Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

Authors:  Alexander Burashnikov
Journal:  J Cardiovasc Pharmacol       Date:  2020-11       Impact factor: 3.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.